Comparative Pharmacology
Head-to-head clinical analysis: CIPROFLOXACIN IN DEXTROSE 5 IN PLASTIC CONTAINER versus FLOXIN IN DEXTROSE 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPROFLOXACIN IN DEXTROSE 5 IN PLASTIC CONTAINER versus FLOXIN IN DEXTROSE 5.
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER vs FLOXIN IN DEXTROSE 5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciprofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, repair, and recombination.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication and transcription.
400 mg intravenously every 8 to 12 hours for most infections; 400 mg every 8 hours for severe/complicated infections.
400 mg intravenously every 12 hours.
None Documented
None Documented
Terminal elimination half-life is 3.5-5 hours in patients with normal renal function. Clinically, this supports twice-daily dosing. In severe renal impairment (CrCl <30 mL/min), half-life may extend to 6-9 hours, requiring dose adjustment.
Terminal elimination half-life: 6-8 hours (prolonged in renal impairment, up to 20-30 hours in severe impairment).
Renal excretion accounts for approximately 50-70% of the dose as unchanged drug via glomerular filtration and tubular secretion; fecal excretion accounts for 15-25%, with about 20% as unchanged drug; biliary excretion contributes minimally (<5%).
Primarily renal (approximately 70-90% unchanged drug), with 5-10% biliary/fecal elimination.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic